BRPI0409032A - método para a produção de micropartìculas à base de emulsão - Google Patents

método para a produção de micropartìculas à base de emulsão

Info

Publication number
BRPI0409032A
BRPI0409032A BRPI0409032-2A BRPI0409032A BRPI0409032A BR PI0409032 A BRPI0409032 A BR PI0409032A BR PI0409032 A BRPI0409032 A BR PI0409032A BR PI0409032 A BRPI0409032 A BR PI0409032A
Authority
BR
Brazil
Prior art keywords
emulsion
production
based microparticles
vessel
methods
Prior art date
Application number
BRPI0409032-2A
Other languages
English (en)
Inventor
Ehud Zeigerson
Original Assignee
Pr Pharmaceuticals
Ehud Zeigerson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pr Pharmaceuticals, Ehud Zeigerson filed Critical Pr Pharmaceuticals
Publication of BRPI0409032A publication Critical patent/BRPI0409032A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/40—Mixing liquids with liquids; Emulsifying
    • B01F23/41—Emulsifying
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/45—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads
    • B01F25/452—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces
    • B01F25/4524—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces the components being pressed through foam-like inserts or through a bed of loose bodies, e.g. balls
    • B01F25/45241—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces the components being pressed through foam-like inserts or through a bed of loose bodies, e.g. balls through a bed of balls
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/14—Powdering or granulating by precipitation from solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)

Abstract

"MéTODOS E APARELHO PARA PREPARAçãO E PRODUçãO DE MICROPARTìCULAS à BASE DE EMULSãO". Para a produção de micropartículas á base de emulsão que contêm um agente biológico ou químico, sendo que o aparelho compreende um vaso; material de compactação situado dentro de tal vaso, e também pode compreender um material que pode ser inserido em ambas as extremidades do dito vaso para encerrar o material de compactação; em uma realização particular, o aparelho é de leito compactado; os métodos incluem a produção de micropartículas à base de emulsão que contêm um agente biológico ou químico; a utilidade da presente invenção é que os aparelhos e os métodos da presente invenção propiciam uma produção não turbulenta de baixo cisalhamento de micropartículas à base de emulsão que resulta em uma distribuição de tamanho de partícula estreita reproduzível, que pode ser utilizada com volumes grandes e pequenos que podem ser convenientemente escalonados para cima enquanto propiciam propriedades de emulsão previsíveis.
BRPI0409032-2A 2003-04-10 2004-04-12 método para a produção de micropartìculas à base de emulsão BRPI0409032A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46186003P 2003-04-10 2003-04-10
PCT/US2004/011485 WO2005003180A2 (en) 2003-04-10 2004-04-12 A method for the production of emulsion-based micro particles

Publications (1)

Publication Number Publication Date
BRPI0409032A true BRPI0409032A (pt) 2006-05-02

Family

ID=33563700

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409032-2A BRPI0409032A (pt) 2003-04-10 2004-04-12 método para a produção de micropartìculas à base de emulsão

Country Status (10)

Country Link
US (2) US8916196B2 (pt)
EP (2) EP1615959B1 (pt)
JP (3) JP2007515392A (pt)
CN (2) CN101410174B (pt)
AU (1) AU2004253853B2 (pt)
BR (1) BRPI0409032A (pt)
CA (1) CA2516107C (pt)
ES (1) ES2427092T3 (pt)
PT (1) PT1615959E (pt)
WO (1) WO2005003180A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2427092T3 (es) * 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CN1852687B (zh) 2003-07-15 2014-01-22 赢创有限公司 控释组合物的制备方法
JP5165240B2 (ja) 2003-07-23 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
CA2700356C (en) * 2007-09-27 2013-07-09 Akina, Inc. Sol-gel phase-reversible hydrogel templates and uses thereof
EP2219620B1 (en) * 2007-11-13 2017-07-19 Surmodics, Inc. Viscous terpolymers as drug delivery platform
WO2009111264A2 (en) 2008-02-29 2009-09-11 Alseres Pharmaceuticals, Inc. Systemic purine administration:modulating axonal outgrowth of central nervous system neurons
US9480643B2 (en) * 2008-12-23 2016-11-01 Surmodics Pharmaceuticals, Inc. Implantable composites and implants comprising same
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
CA2748296C (en) 2008-12-23 2017-03-21 Surmodics Pharmaceuticals, Inc. Implantable composites and compositions comprising releasable bioactive agents
US8951546B2 (en) * 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US9415197B2 (en) * 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US20100189800A1 (en) * 2009-01-23 2010-07-29 Peter Markland Continous double emulsion process for making microparticles
WO2010085608A1 (en) 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
CA2750003A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
CA2784287C (en) * 2009-12-22 2017-07-18 Evonik Degussa Corporation Emulsion-based process for preparing microparticles and workhead assembly for use with same
CN103124592B (zh) * 2010-07-01 2015-05-27 科瓦里斯股份有限公司 使用聚焦声制备用于纳米递送之纳米制剂和系统的组合物和方法
EP2611868B1 (en) 2010-08-30 2020-01-08 Surmodics Pharmaceuticals, Inc. Biodegradable terpolymers and terpolymer blends as pressure-sensitive adhesives
JP2014505585A (ja) * 2010-12-23 2014-03-06 エボニック コーポレイション エマルジョンを製造するための装置および方法
RU2606169C2 (ru) 2011-04-05 2017-01-10 Эдж Терапьютикс Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
WO2014074114A1 (en) 2012-11-09 2014-05-15 Evonik Corporation Drying methods for tuning microparticle properties
US9439864B2 (en) * 2014-07-07 2016-09-13 Antriabio, Inc. Solvent extraction from biodegradable microparticles
JP5801974B1 (ja) * 2015-02-12 2015-10-28 株式会社Ｎｅｘｔコロイド分散凝集技術研究所 多層エマルションの製造方法、及びカプセルの製造方法
JP2019510008A (ja) 2016-02-23 2019-04-11 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド 持続放出性ブプレノルフィンミクロスフェア（ｓｒｂｍ）及びその使用方法
CA3022693A1 (en) * 2016-05-16 2017-11-23 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
GB201615066D0 (en) 2016-09-06 2016-10-19 Ge Healthcare Bioprocess R&D Ab Packed bed emulsification
GB2555658A (en) * 2016-11-01 2018-05-09 Cambridge Consultants Microparticle production
GB201622024D0 (en) * 2016-11-14 2017-02-08 Inventage Lab Inc Apparatus and method for large scale production of monodisperse, microsheric and biodegradable polymer-based drug delivery
EP3651811A1 (en) * 2017-07-10 2020-05-20 Baxalta Incorporated Method for incubating liquids and inactivating viruses
IL272943B2 (en) * 2017-09-03 2024-07-01 Evonik Operations Gmbh Biocompatible polymer powders for additive manufacturing
WO2019104225A1 (en) 2017-11-22 2019-05-31 Dauntless 2, Inc. Therapeutic compound formulations
WO2019161852A2 (de) * 2018-02-26 2019-08-29 Kmitta Kurt Verfahren zum betreiben einer verbrennungskraftmaschine, eine anordnung zur durchführung des verfahrens und eine vorrichtung zur erzeugung einer emulsion
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
WO2020236957A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing end-capped polymers
IL294641B2 (en) 2019-10-31 2024-11-01 Evonik Operations Gmbh A process for preparing nanoparticles or microparticles containing a carrier polymer and one or more biologically active components
CA3210098A1 (en) 2021-02-24 2022-09-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
CN115646232B (zh) * 2022-05-26 2026-01-02 南京中医药大学 一种仅由蛋白质稳定高内相乳液的制备方法
CA3267932A1 (en) 2022-10-05 2024-04-11 Mireca Medicines Gmbh MICROPARCEL AND IMPLANT FORMULATIONS FOR ANALOGUE CGMP THERAPY

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664963A (en) * 1969-10-22 1972-05-23 Balchem Corp Encapsulation process
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
DE2059494B2 (de) * 1970-12-03 1972-03-16 Licentia Gmbh Biegsamer hohlleiter
JPS523342B2 (pt) * 1972-01-26 1977-01-27
US3865352A (en) * 1973-11-16 1975-02-11 Minnesota Mining & Mfg Static mixing device
DE2604832A1 (de) * 1976-02-07 1977-08-11 Basf Ag Verfahren zur analyse von loesungen
US4171981A (en) * 1977-04-29 1979-10-23 The Mead Corporation Process for the production of hot melt coating compositions containing microcapsules
US4183681A (en) 1978-05-19 1980-01-15 Exxon Research & Engineering Co. Emulsion preparation method using a packed tube emulsifier
US4299501A (en) * 1979-08-10 1981-11-10 Ortho Pharmaceutical Corporation Continuous process for the preparation of semisolid dispersions
US4933105A (en) * 1980-06-13 1990-06-12 Sandoz Pharm. Corp. Process for preparation of microspheres
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4501501A (en) * 1983-03-04 1985-02-26 E. I. Du Pont De Nemours And Company Process for dispersing solids in liquid media
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3732370A1 (de) 1987-09-25 1989-04-06 Hoechst Ag Verfahren zur vermischung von lebenden zellen oder mikroorganismen mit einer viskosen fluessigkeit und mischungen, die nach diesem verfahren hergestellt wurden
DK0471036T4 (da) 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
FR2660556B1 (fr) 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.
US6120805A (en) * 1990-04-06 2000-09-19 Rhone-Poulenc Rorer Sa Microspheres, process for their preparation and their use
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
EP2283821A1 (en) 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US5629277A (en) * 1995-10-04 1997-05-13 William L. Brown Paint removing composition
US6140040A (en) * 1995-10-06 2000-10-31 Advanced Minerals Corporation Method of mechanically separating microparticles suspended in fluids using particulate media
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
JPH10109024A (ja) 1996-10-04 1998-04-28 Jasco Corp エマルション調整方法及び装置
JPH10273447A (ja) 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
SE9701161D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
TR200002059T2 (tr) 1998-01-16 2001-01-22 Takeda Chemical Industries, Ltd. Devamlı salınan bileşim, üretim yöntemi ve kullanımı.
JPH11349688A (ja) 1998-06-05 1999-12-21 Reika Kogyo Kk 徐放性複合エマルション、徐放性微粒子及びその製造方法
US6270700B1 (en) * 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
JP3012608B1 (ja) * 1998-09-17 2000-02-28 農林水産省食品総合研究所長 マイクロチャネル装置及び同装置を用いたエマルションの製造方法
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
EP1044683A1 (en) 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
CA2386654A1 (en) * 1999-10-08 2001-04-19 The Procter & Gamble Company Apparatus and process for in-line preparation of hipes
JP3303856B2 (ja) 1999-10-12 2002-07-22 松下電器産業株式会社 液晶表示パネルと製造方法
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
AUPQ529000A0 (en) * 2000-01-28 2000-02-17 Research Laboratories Of Australia Pty Ltd Toner characterization cell
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
CN1507357A (zh) * 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
KR100905142B1 (ko) 2001-01-15 2009-06-29 쓰리엠 이노베이티브 프로퍼티즈 컴파니 가시 파장 영역에서의 높고 평활한 투과율을 가진 다층적외선 반사 필름 및 그로부터 제조된 라미네이트 제품
WO2002058672A2 (en) 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
TWI332407B (en) 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
WO2003092585A2 (en) * 2002-05-02 2003-11-13 Pr Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
EP1829529A1 (en) * 2002-05-03 2007-09-05 PR Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
WO2004078147A2 (en) 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
ES2427092T3 (es) 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
DK2599502T3 (en) 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
CN1852687B (zh) 2003-07-15 2014-01-22 赢创有限公司 控释组合物的制备方法
JP5165240B2 (ja) 2003-07-23 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物

Also Published As

Publication number Publication date
CN102166192A (zh) 2011-08-31
PT1615959E (pt) 2013-08-29
JP5377277B2 (ja) 2013-12-25
JP2013136591A (ja) 2013-07-11
JP2010120948A (ja) 2010-06-03
US10272044B2 (en) 2019-04-30
CA2516107A1 (en) 2005-01-13
EP2548550A1 (en) 2013-01-23
EP1615959A4 (en) 2009-11-25
CA2516107C (en) 2013-12-24
EP1615959A2 (en) 2006-01-18
US20150072928A1 (en) 2015-03-12
WO2005003180A2 (en) 2005-01-13
AU2004253853B2 (en) 2010-04-01
CN101410174A (zh) 2009-04-15
EP1615959B1 (en) 2013-06-05
CN101410174B (zh) 2011-04-06
JP2007515392A (ja) 2007-06-14
ES2427092T3 (es) 2013-10-28
CN102166192B (zh) 2013-09-25
AU2004253853A1 (en) 2005-01-13
US8916196B2 (en) 2014-12-23
WO2005003180A3 (en) 2009-04-02
US20070190154A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
BRPI0409032A (pt) método para a produção de micropartìculas à base de emulsão
Jha et al. Two-dimensional finite element model to study calcium distribution in astrocytes in presence of excess buffer
Sharma Radiation effect on MHD blood flow through a tapered porous stenosed artery with thermal and mass diffusion
Stoll et al. Comprehensive study of the vapour–liquid equilibria of the pure two-centre Lennard–Jones plus pointdipole fluid
Zhu et al. Synthesis and characterization of poly (acrylamide-co-2-acrylamido-2-methylpropane sulfonic acid)/kaolin superabsorbent composite
JP2021500092A5 (pt)
Khamsi Labs on a chip: meet the stripped down rat
Liao et al. Dissolution of a freely rising bubble in aqueous surfactant solutions
Rahawy Treatment of anestrous in buffalo cows by massaging the uterus and ovaries rectally.
TW200712013A (en) The method and apparatus for treatment of wastewater containing insoluble substances
Kee et al. Development of a gel formulation with human umbilical cord mesenchymal stem cell-derived exosomes (UC-MSC-Exo) for cosmetic applications.
Pierre Preconditioning the bidomain model with almost linear complexity
Zeng et al. Numerical simulation on dynamic characteristics of single cavitation bubble near rigid boundary in viscoelastic fluid
Wathoni et al. Characterization, Cytotoxicity Assessment, and In Vivo Evaluation of Chitosan/Alginate Polymeric Nanoparticle-Loaded with a-Mangostin Against Breast Cancer.
Bhati-Kushwaha et al. Applications of Nanotechnology in the Field of Medicine
Cirit et al. Novel Milli-fluidic Human Liver Tissue Chip and Multi-tissue Chip Platform with Continuous Recirculation for Predictive Pharmacokinetic Applications
Karci et al. Impact of different dental implant surfaces on osteoimmunological biomarkers and microbiological parameters‐a randomized clinical trial.
Rai et al. CLAUSTROPHOBIA IN MRI: IS THERE A ROLE FOR DEXMEDETOMIDINE'AN OBSERVATIONAL CASE SERIES STUDY INVOLVING 11 PATIENTS
Boroujeni et al. Enhancement of the Blood-Brain Barrier Permeability due to Interaction of Focused Ultrasound and Nano-Bubbles-In Vitro Sonoporation.
Giordano et al. Imaging systems and algorithms for the numerical characterization of 3D shapes of particle aggregates
Jeerachaipansakul et al. The influence of demineralization process on physicochemical characteristics, BMP-2 quantification of human demineralized tooth matrix.
MF et al. The Use of Elastic Bandage in the Treatment of Palpebral Ptosis in a Patient after Resection of Osteosarcoma of the Jaw.
Akçay et al. The role of glutamate in the neurotoxicity due to exposed to sulfite in the prenatal and/or postnatal period in rats.
Noiriel et al. Self-affine characterisation of fracture surface changes during dissolution
IV et al. THE PROSPECTS TO OBTAINING STEM CELLS FROM ADIPOSE TISSUE BY TECHNOLOGY OF TRACK MEMBRANES.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: PR PHARMACEUTICALS (US) , EHUD ZEIGERSON (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25B Requested transfer of rights rejected

Owner name: PR PHARMACEUTICALS (US) , EHUD ZEIGERSON (US)

B15G Petition not considered as such [chapter 15.7 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: PR PHARMACEUTICALS (US) , EHUD ZEIGERSON (US)

B25E Requested change of name of applicant rejected

Owner name: PR PHARMACEUTICALS (US) , EHUD ZEIGERSON (US)

B12F Other appeals [chapter 12.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2580 DE 16/06/2020.